# US 2010/0168240 A1 · Substituted dibenzoic acid derivatives and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168240 A1
- Document ID: US20100168240A1
- Status: Published application
- Kind: A1
- Application number: 12/529,713
- Filed: 2008-03-15
- Published: 2010-07-01
- Earliest claimed: 2007-03-29
- Assignees: Bayer Schering Pharma Aktiengesellschaft
- Inventors: Michael Hahn; Eva-Maria Becker; Andreas Knorr; Dirk Schneider; Johannes-Peter Stasch; Karl-Heinz Schlemmer; Frank Wunder; Dieter Lang
- Web page: https://patentgrep.com/patent/US20100168240A1

## CPC

- C07C 65/28: having unsaturation outside the aromatic rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/10: for impotence
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/10: Antimycotics
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to novel substituted dibenzoic acid derivatives of formula (I), wherein A represents a group of formula (II) or (III), to methods for producing the same, and to their use in the treatment and/or prophylaxis of diseases. The invention also relates to the use of said substances in the production of drugs for the treatment and/or prophylaxis of diseases, especially in the treatment and/or prevention of cardiovascular diseases.

## Claims

### Claim 1

A compound of the formula (I)
in which
A represents a group of the formula
in which * represents the point of attachment to group D and
E represents a bond, —CH2—, —CH2—CH2— or —CH═CH—,
D represents a bond or represents (C1-C7)-alkanediyl, (C2-C6)-alkanediyl-O—#, (C2-C7)-alkenediyl or (C2-C7)-alkynediyl, each of which may be mono- or polysubstituted by fluorine and in which # represents the point of attachment to group A,
R1, R2, R3, R4, R5 and R6 independently of one another represent a substituent selected from the group consisting of halogen, (C1-C6)-alkyl, (C1-C6)-alkoxy, cyano and nitro, where alkyl and alkoxy for their part may be mono- or polysubstituted by fluorine, and
n, o, p, q, r and s independently of one another each represent the number 0, 1, 2, 3 or 4, where, if R1, R2, R3, R4, R5 or R6 is present more than once, their meanings may in each case be identical or different,
and the salts, solvates and solvates of the salts thereof.

### Claim 2 (depends on 1)

The compound of the formula (I) as claimed in claim 1, in which
A represents a group of the formula
in which * represents the point of attachment to group D,
D represents a bond or (C1-C7)-alkanediyl,
R1, R4, R5 and R6 independently of one another represent a substituent selected from the group consisting of fluorine, chlorine, bromine, (C1-C4)-alkyl, trifluoromethyl, (C1-C4)-alkoxy and trifluoromethoxy,
n, q, r and s independently of one another each represent the number 0, 1 or 2, where, if R1, R4, R5 or R6 is present more than once, their meanings may in each case be identical or different,
R2 and R3 each represent fluorine, and
o and p independently of one another each represent the number 0 or 1,
and the salts, solvates and solvates of the salts thereof.

### Claim 3 (depends on 1)

The compound as claimed in claim 1 of the formula (I-A)
in which
D represents (C1-C7)-alkanediyl,
R1 represents hydrogen or fluorine,
R4 represents a substituent selected from the group consisting of fluorine, chlorine, methyl, tent-butyl, trifluoromethyl, methoxy and trifluoromethoxy, and
q represents the number 0, 1 or 2,
where, if the substituent R4 is present twice, its meanings may be identical or different,
and the salts, solvates and solvates of the salts thereof.

### Claim 4 (depends on 1)

A process for preparing a compound of the formula (I) or (I-A) as defined in claim 1 wherein compounds of the formula (II)
in which R2, R3, o and p each have the meanings given in claim 1 and
T1 and T2 are identical or different and represent (C1-C4)-alkoxycarbonyl,
are either
[A] converted in an inert solvent in the presence of a base with a compound of the formula (III-A)
in which A, D, R1 and n each have the meanings given in claim 1 and
L represents phenyl or o-, m- or p-tolyl and
X represents halide or tosylate,
into compounds of the formula (IV-A)
in which A, D, R1, R2, R3, n, o, p, T1 and T2 each have the meanings given above, or
[B] converted in an inert solvent in the presence of a base with a compound of the formula (III-B)
in which R1, n, L and X each have the meanings given above,
initially into compounds of the formula (IV-B)
in which R1, R2, R3, n, o, p, T1 and T2 each have the meanings given above,
and these are then coupled in an inert solvent in the presence of a base with a compound of the formula (V)
A-D-Q (V),
in which A and D have the meanings given in claim 1 and
Q represents a leaving group, such as, for example, halogen, tosylate or mesylate,
to give compounds of the formula (IV-C)
in which A, D, R1, R2, R3, n, o, p, T1 and T2 each have the meanings given above,
and the resulting compounds of the formula (IV-A) or (IV-C) are then converted by hydrolysis of the ester groups T1 and T2 into the dicarboxylic acids of the formula (I),
and the compounds of the formula (I) are separated where appropriate by methods known to the skilled person into their enantiomers and/or diastereomers, and/or where appropriate reacted with the appropriate (i) solvents and/or (ii) bases or acids to give the solvates, salts and/or solvates of the salts thereof.

### Claim 6 (depends on 1)

The compound as defined in claim 1 for the treatment and/or prevention of diseases.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a compound as defined in claim 1 in combination with an inert, non-toxic, pharmaceutically suitable excipient.

### Claim 9

The pharmaceutical composition further comprising one or more further active ingredients selected from the group consisting of organic nitrates, NO donors, cGMP-PDE inhibitors, stimulators of guanylate cyclase, agents having antithrombotic activity, agents lowering blood pressure, and agents altering lipid metabolism.

### Claim 10 (depends on 7)

The pharmaceutical composition as claimed in claim 7 for the treatment and/or prevention of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemias, vascular disorders, thromboembolic disorders and arteriosclerosis.

### Claim 11 (depends on 1)

A method for the treatment and/or prevention of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemias, vascular disorders, thromboembolic disorders and arteriosclerosis in humans and animals by administration of an effective amount of at least one compound as defined in claim 1.

### Claim 12 (depends on 7)

A method for the treatment and/or prevention of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemias, vascular disorders, thromboembolic disorders and arteriosclerosis in humans and animals by administration of an effective amount of a pharmaceutical composition of claim 7.
